



# **Advanced Collaborative Emissions Study (ACES)**

Cooperative multi-party effort to characterize emissions and possible health effects of new advanced heavy duty engine and control systems and fuels in the market 2007 – 2010.

#### **DOE Merit Review June 2011**

<u>D. Greenbaum<sup>1</sup></u>, J. McDonald<sup>2</sup>, C. Tennant<sup>3</sup>, R. Shaikh<sup>1</sup>, M. Costantini<sup>1</sup>, A van Erp<sup>1</sup>, B. Bailey<sup>3</sup> <sup>1</sup>Health Effects Institute (HEI), <sup>2</sup>Lovelace Respiratory Research Institute, and <sup>3</sup>Coordinating Research Council (CRC)

This presentation does not contain any proprietary or confidential information

ID # ACE044 NETL Agreement 13919

# **Project Overview**

#### Phases:

- 1. 2007 Engine Emissions Characterization (Southwest Research Institute<sup>®</sup> (SWRI<sup>®</sup>))
  - CRC Technical Leader
- 2. 2010 Engine Emissions Characterization
  - CRC Technical Leader
- 3. 2007/2010 Engine Health Effects Testing (Lovelace Respiratory Research Institute (LRRI)
  - Short Term biological screening and Long-Term Health Effects Test on 2007 Engines
  - HEI Technical Leader ; CRC Technical Monitor

#### **Funding**

Overall Project: \$15.5 million

- Total DOE Contract: \$5.95 million (Contractor Share: \$3.98 million)
  - FY 10 DOE Funding: \$500,000
  - FY 11 DOE Funding: \$700,000 (planned)

#### Partners

- DOE OVT and NETL
- Engine Manufacturers Association (EMA)
- US Environmental Protection Agency (EPA)
- California Air Resources Board (ARB)
- American Petroleum Institute (API)
- Aftertreatment Manufacturers
- Coordinating Research Council (CRC)



Slight delays in Phase 2, 3



	2	007	2	800	20	09	20	10	20	011		20	12		20	13
Phase 1: Testing																
Phase 1: Analysis & Reporting																
Phase 2: Testing																
Phase 2: Analysis & Reporting																
Phase 3: Facilities Development					T											
Phase 3: Animal Biological Screening and Health Testing																
Phase 3: Analysis & Reporting																

### RELEVANCE: Evaluating Emissions of Advanced Technology Diesels

- DOE OVT MYPP Advanced Combustion R and D: New Generation diesel engines are highly fuel efficient and a likely significant contributor to enhanced fuel economy for the next 15 – 20 years IF they gain wide acceptance
- The combination of advanced-technology, compression-ignition engines, aftertreatment systems, reformulated fuels and reformulated oils developed to meet the 2007/2010 emission standards will result in substantially reduced emissions.
- Substantial public health benefits and enhanced public acceptance and use are expected from these reductions.
- With any new technology it is prudent to conduct research to confirm benefits and to ensure that there are no adverse impacts to public health and welfare.

### **Overall Objective**

 to characterize emissions and possible health effects of new advanced heavy duty engine and control systems and fuels in the market 2007 – 2010

### HEI ACES Oversight Committee

Mark Utell, Chair	University of Rochester	David Kittelson	University of Minnesota
Richard Albertini	University of Vermont	Eugene McConnell	Consultant, Former NTP Director
Ken Demerjian	SUNY Albany	Gunter Oberdorster	University of Rochester
Helmut Greim	Technical University of Munich	Charles Plopper	University of California, Davis
Uwe Heinrich	Fraunhofer Institute	Howard Rockette	University of Pittsburgh
Tom Kensler	Johns Hopkins University	James Swenberg	University of North Carolina, Chapel Hill

### Partners: CRC ACES Panel

Reynaldo Agama	Caterpillar	M. Matti Maricq	Ford Motor Company				
James Ball	Formerly Ford Motor Company	Mani Natarajan	Marathon Petroleum Company LLC				
Nicholas Barsic	John Deere	Ralph Nine	US Department of Energy / NETL				
Steve Berry	Volvo	Robert Okamoto California Air Resources					
Steven Cadle	Formerly General Motors R&D Center	Charles Schleyer ExxonMobil					
Timothy French	Engine Manufacturers Association	Shirish Shimpi	Cummins				
Thomas Hesterberg	International	Joseph Somers	US Environmental Protection Agency				
Donald Keski-Hynnila	Detroit Diesel	Chris Tennant	CRC				
Chris Laroo	US Environmental Protection Agency	Steve Trevitz	Volvo				
Douglas Lawson	National Renewable Energy Laboratory	Urban Wass	Volvo				
Hector Maldonado	California Air Resources Board	Rashid Shaikh	Health Effects Institute				

# ACES Phase I Approach and Objectives

- Quantify the significant reduction in both regulated and unregulated emissions from advanced diesel engines,
- Provide regulated and unregulated emissions for this new engine technology,
- Provide initial guidance for ACES Phase 3 health study using the regulated and unregulated emissions information from ACES Phase 1
- Heavy Heavy Duty (Class 8) Engines from: Caterpillar, Cummins, Detroit Diesel, and Volvo

## Summary – Phase 1 Results

- Regulated PM, CO, and NMHC emissions were at least 90% below the 2007 standard, and NO<sub>x</sub> was 10% below standard
- Most unregulated emissions at least 90% below 2004 technology
- Average NO<sub>2</sub> emission of 0.68 g/hp-hr was 2 to 7 times higher than the emissions from 2004 engines
  - However, 2010 engine technology  $NO_x$  limit of 0.20 g/hp-hr will force  $NO_2$  emissions to be substantially lower than both 2007 and 2004 technology engines
- Particle number emissions <u>average</u> was at least 90% below 2004 technology engines, even when DPF regeneration occurred
- Elemental carbon represented only 7 % of total PM mass, and the hydrated sulfuric acid determined from measured sulfate was the dominant PM component for the 16-Hour Cycle, 70 percent of total PM mass
- The final report issued June 30, 2009

# ACES PHASE 2: 2010 Compliant Engines Approach and Objectives

- 2010 engines will offer substantial improvements in NOx emissions
- Phase 2 will conduct both Emissions Characterization and some possible Health Testing in 2010-compliant engines
- 2010 technology has evolved in multiple directions and, given credits, will not meet the specific requirements by that date
  - Testing likely to be on "2011" engines
- CRC actively planning with manufacturers, agencies, other sponsors for start in 2011

### ACES PHASE 3 Health Bioscreening Approach and Objectives

Phase 3A: Characterization of emissions and exposure atmospheres

Phase 3B: Conduct of animal bioscreening studies

DOE Funding:

- Characterization of animal exposures
- 3 month mouse pulmonary bioscreening

**EPA Funding (leveraged by DOE investment):** 

- Long-term rat carcinogenesis bioassay
- Pulmonary bioscreening at 1, 3, 12 & 24 mo


### PHASE 3A

- 2007-compliant "engine B' " (selected from four candidates)
  - Installed at LRRI in facility created under preceding contract
  - Confirmed that engine/control systems met performance criteria

Steady-state (SS) and Federal Test Procedure (FTP) cycles 16-hr ACES cycle (4 repeats of 4 hr cycle with cold start)


- Evaluated diluted emissions in empty animal chamber, and compared to SwRI results (using same fuel)
  - Emissions = exhaust + crankcase blow-by
  - FTP, SS modes 1, 3 & 5, ACES cycle
  - Constant pressure primary dilution tunnel
- Determined dilutions required to meet targets set by HEI
  - Dilutions set to achieve 4.2, 0.8 & 0.1 ppm NO<sub>2</sub>
  - Dilutions ≈ 40:1, 210:1 & 1680:1
- PM levels are <u>very low</u>; study may primarily detect effects of NO<sub>2</sub> if any effects are seen

### **Engine and Primary Dilution System**





### Exhaust Extraction and Secondary Dilution Systems



(Note: Drawing is not to scale)



Exposure Atmosphere and Operational Criteria


**Exposures Initiated February 21** 

Additional measurements include Particle Mass (inlet and chamber) and CO, CO<sub>2</sub>, and Total Hydrocarbons from High Level. Size measured at each level once/week.

Exposures conducted 16 hrs/day, 5 days per week Exposure chamber temperatures require <26.7°C


Protocol defines actionable limits for engine system performance

Based on: NOx (within 100 % of Daily Tunnel Concentrations) Black Carbon (< 15 μg/m<sup>3</sup>) Particle Mass (<100 μg/m<sup>3</sup>) Diesel particle trap (DPF) pressure (<3.8 lbs/sq inch) Power/Torque on Engine Maps (20 % of Target)






#### Chamber real-time gas data at High Target






#### ACES 16-Hr Cycle Dekati, DMM Mass Concentration






# Real-time particle number concentration (FMPS)






# Real-time PM size distribution (FMPS)






## Chamber Atmosphere Composition Particulate Matter





## Chamber Atmosphere Composition Semivolatile Organics



#### CORE BIOSCREENING STUDY: DESIGN 3-Month Exposure of C57BL/6 Mice:

- Expose 120/group 16 hr/day, 5 days/wk for 3 months (13 wk)
- 60/group allocated for evaluation at 1 & 3 months

Lung lavage & cell proliferation Hematology & serum chemistry (3 mo) Save tissues for histopathology (evaluation not budgeted)

#### **Chronic Carcinogenicity Bioassay of Wistar Han Rats:**

- Expose 288/group 16 hr/day, 5 days/wk for 24-30 months
- 3 dilutions of whole emissions + clean air controls
- 166/group committed to carcinogenesis bioassay ~ 80% power to detect 10% difference from control
- 122/group allocated for interim evaluations at 1, 3, 12, & 24 months

Pulmonary function (3, 12, & 24 mo) Lung lavage & cell proliferation Hematology & serum chemistry (3, 12, & 24 mo) Histopathology

#### Accommodate ancillary biological studies of rats and mice

• Markers of potential Cancer, vascular inflammation effects



#### **CORE BIOSCREENING STUDY: STATUS**

- 1- and 3-month exposures of both rats and mice complete; Rats now in Month 10 of long term exposure
- 1- and 3-month Health Evaluations complete at LRRI, 3 of 5 Ancillary Study Sites
- Statistical analysis underway
- Preliminary results presented to Oversight/Advisory Committee April 26, 2011
- Mice and rats generally healthy and gaining weight as expected
  - Updated details at presentation

# Preliminary Findings: Rodent 1 and 3 Month Sacrifices

The majority of the analyses showed <u>no difference</u> between diesel exhaust exposure and clean air control.

<u>Histopathology</u> analysis revealed mild exposure-related hyperplasia in the rats after 3 months of exposure, but not in mice.

Statistical findings were noted for several pathology indicators of <u>pulmonary</u> <u>stress and inflammation</u> in rats; some indications in mice as well.

<u>Pulmonary function</u> assessments in rats showed slight statistical differences in exposed rats compared with control after 3 months of exposure.


*Note*: When designing the study, it was expected that at the high concentration (at 4.2 ppm  $NO_2$ ) some  $NO_2$ -related effects may be observed. Results so far are not inconsistent with that.

## **Preliminary Findings:** Pulmonary Inflammation/Stress in rats at 3 **Months** (DO NOT QUOTE OR CITE)

\*p<0.01


HIGH

Mid




### Preliminary Findings: Neutrophils in Mouse Lung Fluid at 3 Months (DO NOT QUOTE OR CITE)

Mouse BALavage




### Preliminary Findings: IL-6 in Mouse Lung Tissue at 1 Month (DO NOT QUOTE OR CITE)

Lung Tissue Mice



### Preliminary Findings: Pulmonary Function in Rats at 3 Months (DO NOT QUOTE OR CITE)



Significant (p<0.05) trend observed for each of these endpoints

### SUMMARY

- The study is progressing smoothly, and according to protocol
- No significant difficulties have been encountered with the engine or exposure systems; 1- and 3-month exposures now complete
- All operational parameters have been well within protocol limits; Cumulative mean NO<sub>2</sub> concentrations are acceptably close to target.
- Both mice and rats have apparently tolerated exposure well to date
- Preliminary health results suggest possible increase in markers of effect at high exposure levels
  - This has NOT been fully analyzed or peer-reviewed
  - Results may be consistent with effects of NO<sub>2</sub>-only exposures seen in other studies
- Reporting of shorter-term exposure results is entering review; publication expected in early 2012

# For further information, contact:

Annemoon van Erp	Maria Costantini					
Senior Scientist	Principal Scientist					
Health Effects Institute						
avanerp@healtheffects.org	mcostantini@healtheffects.org					
Chris Tennant						
Deputy Director						
Coordinating Research Council						
ctennant@crcao.org						
_						



